Rockwell Medical, Inc. (RMTI)
USD 1.06
(-0.93%)
USD 1.06
(-0.93%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 15.37 Million USD | -26.29% |
| 2022 | 20.85 Million USD | -25.29% |
| 2021 | 27.91 Million USD | -10.37% |
| 2020 | 31.14 Million USD | -15.67% |
| 2019 | 36.93 Million USD | 23.84% |
| 2018 | 29.82 Million USD | 0.67% |
| 2017 | 29.62 Million USD | 9.88% |
| 2016 | 26.96 Million USD | 12.15% |
| 2015 | 24.04 Million USD | -7.91% |
| 2014 | 26.1 Million USD | -51.41% |
| 2013 | 53.71 Million USD | -11.87% |
| 2012 | 60.95 Million USD | 123.05% |
| 2011 | 27.32 Million USD | 114.68% |
| 2010 | 12.72 Million USD | -4.78% |
| 2009 | 13.36 Million USD | 20.42% |
| 2008 | 11.1 Million USD | 67.24% |
| 2007 | 6.63 Million USD | -10.77% |
| 2006 | 7.43 Million USD | 159.43% |
| 2005 | 2.86 Million USD | 19.67% |
| 2004 | 2.39 Million USD | 1.21% |
| 2003 | 2.36 Million USD | 2.24% |
| 2002 | 2.31 Million USD | -1.56% |
| 2001 | 2.35 Million USD | -2.12% |
| 2000 | 2.4 Million USD | 0.15% |
| 1999 | 2.4 Million USD | 4.35% |
| 1998 | 2.3 Million USD | 35.29% |
| 1997 | 1.7 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 4.38 Million USD | 28.42% |
| 2024 Q2 | 4.03 Million USD | -8.04% |
| 2023 FY | 15.37 Million USD | -26.29% |
| 2023 Q4 | 3.41 Million USD | -13.25% |
| 2023 Q1 | 4.02 Million USD | -6.5% |
| 2023 Q2 | 3.99 Million USD | -0.84% |
| 2023 Q3 | 3.93 Million USD | -1.33% |
| 2022 Q1 | 5.84 Million USD | -4.7% |
| 2022 Q2 | 6.22 Million USD | 6.63% |
| 2022 Q3 | 4.48 Million USD | -27.97% |
| 2022 Q4 | 4.3 Million USD | -3.99% |
| 2022 FY | 20.85 Million USD | -25.29% |
| 2021 Q1 | 7.58 Million USD | -10.33% |
| 2021 Q3 | 6.64 Million USD | -12.14% |
| 2021 Q4 | 6.12 Million USD | -7.75% |
| 2021 Q2 | 7.56 Million USD | -0.29% |
| 2021 FY | 27.91 Million USD | -10.37% |
| 2020 Q2 | 6.48 Million USD | -29.27% |
| 2020 FY | 31.14 Million USD | -15.67% |
| 2020 Q4 | 8.45 Million USD | 20.2% |
| 2020 Q3 | 7.03 Million USD | 8.51% |
| 2020 Q1 | 9.16 Million USD | 7.67% |
| 2019 Q2 | 10.67 Million USD | 8.69% |
| 2019 Q1 | 9.82 Million USD | -7.44% |
| 2019 FY | 36.93 Million USD | 23.84% |
| 2019 Q4 | 8.51 Million USD | 7.43% |
| 2019 Q3 | 7.92 Million USD | -25.75% |
| 2018 Q4 | 10.6 Million USD | 52.27% |
| 2018 Q3 | 6.96 Million USD | -3.9% |
| 2018 FY | 29.82 Million USD | 0.67% |
| 2018 Q1 | 6.72 Million USD | -15.86% |
| 2018 Q2 | 7.24 Million USD | 7.75% |
| 2017 FY | 29.62 Million USD | 9.88% |
| 2017 Q4 | 7.99 Million USD | 31.17% |
| 2017 Q3 | 6.09 Million USD | -25.81% |
| 2017 Q2 | 8.21 Million USD | 12.32% |
| 2017 Q1 | 7.31 Million USD | 0.9% |
| 2016 Q1 | 6.3 Million USD | -22.39% |
| 2016 FY | 26.96 Million USD | 12.15% |
| 2016 Q4 | 7.25 Million USD | 14.5% |
| 2016 Q2 | 7.07 Million USD | 12.32% |
| 2016 Q3 | 6.33 Million USD | -10.54% |
| 2015 Q2 | 4.72 Million USD | -22.93% |
| 2015 Q4 | 8.11 Million USD | 60.0% |
| 2015 FY | 24.04 Million USD | -7.91% |
| 2015 Q1 | 6.12 Million USD | -19.38% |
| 2015 Q3 | 5.07 Million USD | 7.49% |
| 2014 Q2 | 4.4 Million USD | -49.45% |
| 2014 Q4 | 7.59 Million USD | 40.67% |
| 2014 Q3 | 5.4 Million USD | 22.72% |
| 2014 Q1 | 8.7 Million USD | -9.21% |
| 2014 FY | 26.1 Million USD | -51.41% |
| 2013 Q1 | 16.67 Million USD | 8.35% |
| 2013 FY | 53.71 Million USD | -11.87% |
| 2013 Q4 | 9.58 Million USD | -31.5% |
| 2013 Q3 | 13.99 Million USD | 3.99% |
| 2013 Q2 | 13.46 Million USD | -19.26% |
| 2012 Q2 | 13.7 Million USD | 11.35% |
| 2012 Q4 | 15.38 Million USD | -21.35% |
| 2012 FY | 60.95 Million USD | 123.05% |
| 2012 Q1 | 12.3 Million USD | 17.19% |
| 2012 Q3 | 19.56 Million USD | 42.79% |
| 2011 FY | 27.32 Million USD | 114.68% |
| 2011 Q4 | 10.49 Million USD | 61.72% |
| 2011 Q3 | 6.49 Million USD | 14.18% |
| 2011 Q2 | 5.68 Million USD | 22.31% |
| 2011 Q1 | 4.64 Million USD | 10.81% |
| 2010 Q3 | 3.15 Million USD | 18.66% |
| 2010 Q1 | 2.71 Million USD | -8.92% |
| 2010 Q2 | 2.66 Million USD | -1.83% |
| 2010 FY | 12.72 Million USD | -4.78% |
| 2010 Q4 | 4.19 Million USD | 32.8% |
| 2009 Q1 | 2.89 Million USD | -13.73% |
| 2009 Q4 | 2.97 Million USD | -24.11% |
| 2009 Q2 | 3.56 Million USD | 23.05% |
| 2009 FY | 13.36 Million USD | 20.42% |
| 2009 Q3 | 3.92 Million USD | 10.01% |
| 2008 FY | 11.1 Million USD | 67.24% |
| 2008 Q1 | 2.21 Million USD | 9.0% |
| 2008 Q4 | 3.36 Million USD | 1.6% |
| 2008 Q2 | 2.22 Million USD | 0.41% |
| 2008 Q3 | 3.3 Million USD | 48.89% |
| 2007 FY | 6.63 Million USD | -10.77% |
| 2007 Q3 | 1.5 Million USD | -3.75% |
| 2007 Q2 | 1.55 Million USD | 0.68% |
| 2007 Q1 | 1.54 Million USD | -27.8% |
| 2007 Q4 | 2.02 Million USD | 35.25% |
| 2006 FY | 7.43 Million USD | 159.43% |
| 2006 Q3 | 2.21 Million USD | 10.45% |
| 2006 Q1 | 1.07 Million USD | 39.07% |
| 2006 Q4 | 2.14 Million USD | -3.13% |
| 2006 Q2 | 2 Million USD | 86.59% |
| 2005 Q2 | 688.46 Thousand USD | 6.3% |
| 2005 Q3 | 758.81 Thousand USD | 10.22% |
| 2005 Q4 | 772.66 Thousand USD | 1.82% |
| 2005 FY | 2.86 Million USD | 19.67% |
| 2005 Q1 | 647.65 Thousand USD | 1.73% |
| 2004 Q2 | 582.97 Thousand USD | 2.2% |
| 2004 Q4 | 636.62 Thousand USD | 5.0% |
| 2004 FY | 2.39 Million USD | 1.21% |
| 2004 Q1 | 570.41 Thousand USD | -12.31% |
| 2004 Q3 | 606.3 Thousand USD | 4.0% |
| 2003 Q4 | 650.49 Thousand USD | 10.54% |
| 2003 Q2 | 608.59 Thousand USD | 16.98% |
| 2003 Q1 | 520.23 Thousand USD | -14.96% |
| 2003 FY | 2.36 Million USD | 2.24% |
| 2003 Q3 | 588.45 Thousand USD | -3.31% |
| 2002 Q3 | 557.98 Thousand USD | -9.76% |
| 2002 Q4 | 611.72 Thousand USD | 9.63% |
| 2002 Q1 | 527.86 Thousand USD | -11.03% |
| 2002 FY | 2.31 Million USD | -1.56% |
| 2002 Q2 | 618.36 Thousand USD | 17.14% |
| 2001 Q1 | 538.04 Thousand USD | -9.12% |
| 2001 FY | 2.35 Million USD | -2.12% |
| 2001 Q4 | 593.32 Thousand USD | -4.99% |
| 2001 Q3 | 624.48 Thousand USD | 4.65% |
| 2001 Q2 | 596.7 Thousand USD | 10.9% |
| 2000 Q3 | 610.18 Thousand USD | -6.8% |
| 2000 Q2 | 654.69 Thousand USD | 19.77% |
| 2000 Q1 | 546.61 Thousand USD | -8.9% |
| 2000 Q4 | 592.03 Thousand USD | -2.97% |
| 2000 FY | 2.4 Million USD | 0.15% |
| 1999 Q1 | 600 Thousand USD | 0.0% |
| 1999 Q4 | 600 Thousand USD | 0.0% |
| 1999 Q3 | 600 Thousand USD | 0.0% |
| 1999 FY | 2.4 Million USD | 4.35% |
| 1999 Q2 | 600 Thousand USD | 0.0% |
| 1998 Q4 | 600 Thousand USD | 0.0% |
| 1998 FY | 2.3 Million USD | 35.29% |
| 1998 Q1 | 500 Thousand USD | 25.0% |
| 1998 Q2 | 500 Thousand USD | 0.0% |
| 1998 Q3 | 600 Thousand USD | 20.0% |
| 1997 Q4 | 400 Thousand USD | 0.0% |
| 1997 FY | 1.7 Million USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -86.287% |
| Alpha Teknova, Inc. | 45.85 Million USD | 66.476% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 92.155% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 65.724% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 90.343% |
| Cosmos Health Inc. | 26.18 Million USD | 41.278% |
| Journey Medical Corporation | 54.59 Million USD | 71.839% |
| Embecta Corp. | 528.4 Million USD | 97.09% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 94.346% |
| Dynavax Technologies Corporation | 219.14 Million USD | 92.985% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 97.394% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 95.289% |
| PainReform Ltd. | 9.58 Million USD | -60.413% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -17.14% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -17.14% |
| SCYNEXIS, Inc. | 51.84 Million USD | 70.348% |
| Safety Shot Inc | 12.1 Million USD | -26.956% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -400.914% |
| Procaps Group, S.A. | 199.47 Million USD | 92.293% |
| Theratechnologies Inc. | 72.75 Million USD | 78.869% |
| Harrow Health, Inc. | 89.97 Million USD | 82.913% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -62.757% |
| Biofrontera Inc. | 39.95 Million USD | 61.526% |
| DURECT Corporation | 43.71 Million USD | 64.831% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 97.094% |
| Cronos Group Inc. | 96.7 Million USD | 84.103% |
| OptiNose, Inc. | 85.1 Million USD | 81.935% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 93.377% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 60.734% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 260.799% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 95.106% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -57.993% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 64.28% |
| Radius Health, Inc. | 265.92 Million USD | 94.219% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -11.069% |
| ProPhase Labs, Inc. | 37.85 Million USD | 59.384% |
| Phibro Animal Health Corporation | 260.29 Million USD | 94.094% |
| Procaps Group S.A. | 187.24 Million USD | 91.789% |
| Alvotech | 285.43 Million USD | 94.614% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -56.478% |
| Viatris Inc. | 5.96 Billion USD | 99.742% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 74.308% |
| SIGA Technologies, Inc. | 22.04 Million USD | 30.255% |
| Tilray Brands, Inc. | 251.35 Million USD | 93.884% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 68.649% |
| Shineco, Inc. | 17.94 Million USD | 14.342% |
| PetIQ, Inc. | 192.72 Million USD | 92.023% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -285.203% |
| Incannex Healthcare Limited | 30.05 Million USD | 48.844% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 99.037% |
| Alimera Sciences, Inc. | 62.64 Million USD | 75.457% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -1916.283% |
| Assertio Holdings, Inc. | 368.58 Million USD | 95.829% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -161.215% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | 13.671% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | 27.375% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 26.937% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 90.681% |
| Hempacco Co., Inc. | 7.59 Million USD | -102.384% |
| Talphera, Inc. | 11.99 Million USD | -28.181% |
| Alvotech | 285.43 Million USD | 94.614% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 89.074% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 95.542% |
| Currenc Group, Inc. | 24 Million USD | 35.947% |
| Kamada Ltd. | 45.42 Million USD | 66.156% |
| Indivior PLC | 911 Million USD | 98.312% |
| Evoke Pharma, Inc. | 12.4 Million USD | -23.888% |
| Flora Growth Corp. | 10.57 Million USD | -45.326% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 26.937% |
| Evolus, Inc. | 189.75 Million USD | 91.898% |
| HUTCHMED (China) Limited | 436.23 Million USD | 96.476% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 90.026% |
| Akanda Corp. | 3.48 Million USD | -341.337% |